Guan, X., L. Wang, Y. Cao, F. Shi, H. Xu, J. Ding, M. Wu, and H. Li. “A Erratum on Cost Effectiveness Analysis of Blonanserin Versus Ziprasidone As First-Line Treatment for Patients With Schizophrenia in China”. Health Decision, vol. 1, Nov. 2023, doi:10.54844/hd.2023.0498.